Skip to main content

poster

Routine implementation of pharmacogenomic testing for mental health and other conditions treated in primary care may require overcoming barriers such as cost to the patient and knowledge ...
10/26/2023
Valbenazine is indicated for once-daily treatment of tardive dyskinesia (TD), a movement disorder associated with prolonged antipsychotic exposure. Data from 3 long-term studies (KINECT™-...
10/26/2023
Veterans Intensive Primary Care Mental Health Integration Bootcamp (VIP Bootcamp): An upstream solution to Mental Health(MH) access issues within the VA system
10/26/2023
Results of a phase IV, open-label safety study evaluating viloxazine ER (Qelbree®) administered with psychostimulants in pediatric (6-17 years) ADHD; morning vs. evening administration of...
10/26/2023
Catatonia is a psychomotor syndrome with well-defined clinical characteristics, although the neurological mechanisms involved remain unknown. In this study, we report a case of a patient ...
10/26/2023
In the SKYLARK Study, zuranolone 50 mg was generally well tolerated in adults with postpartum depression; treatment-emergent adverse events (TEAEs) led to zuranolone dose reduction and di...
10/26/2023
The Rapid Mood Screener (RMS) is a self-administered screening tool to help differentiate bipolar I disorder from major depressive disorder. Cases were identified from a primary care sett...
10/26/2023
This case report discusses the safety and efficacy of VMAT2 inhibitors in treating antipsychotic induced tardive dyskinesia in adults >55 years old. It also highlights the increased ri...
10/26/2023
The subject matter of the poster includes a case report of a patient with treatment refractory catatonia whose condition rapidly improved following a game of chess, one of the patient's k...
10/26/2023
This study examined the utilization pattern of augmentation with atypical antipsychotics after partial or no response to antidepressants in patients with MDD. The antidepressant prescript...
10/26/2023